Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial-Reference-Cited by-同舟云学术

Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial

Published:2018-05-17 Issue:3 Volume:6 Page:e00402
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol Res Perspect

Author:

Roepcke Stefan¹^ORCID,Plock Nele¹,Yuan Josh²,Fedyk Eric R.²,Lahu Gezim¹,Zhao Lin²,Smithson Glennda²

Affiliation:

1. Takeda Pharmaceuticals International AG; Zurich Switzerland

2. Takeda Pharmaceuticals International; Cambridge Massachusetts

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Reference26 articles.

1. SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature;Becker;PLoS One,2013

2. B cells in rheumatoid arthritis: From pathogenic players to disease biomarkers;Bugatti;Biomed Res Int,2014

3. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors;Weers;J Immunol,2011

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection;International Journal of Molecular Sciences;2022-10-22

2. Effect of CD38 on B‐cell function and its role in the diagnosis and treatment of B‐cell‐related diseases;Journal of Cellular Physiology;2022-04-29

3. Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings;mAbs;2021-01-01

4. Repositioning drugs for systemic lupus erythematosus;Systemic Lupus Erythematosus;2021

5. Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD+ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells;Cancers;2020-12-30